Loading
Loading
Tissue Repair & Recovery · 50mg
Choose dose
Janoshik-tested · 10 vials per kit
SS-31 (Elamipretide) is a mitochondria-targeted peptide studied in preclinical research for its cytoprotective and bioenergetic properties. Research has examined its potential to protect mitochondrial structure and function, reduce oxidative stress, and increase ATP production to improve cellular energy metabolism. Studies have explored applications in conditions associated with mitochondrial dysfunction, including heart failure and neurodegenerative disease models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
SS-31
Elamipretide
SS-31 (Elamipretide / MTP-131) is a synthetic aromatic-cationic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively concentrates at the inner mitochondrial membrane. Developed at Cornell University by Hazel Szeto and Peter Schiller, it is among the most well-characterised mitochondria-targeted research peptides and is in clinical development for heart failure and Barth syndrome.
SS-31 binds directly to cardiolipin — a phospholipid exclusively located in the inner mitochondrial membrane that serves as a structural anchor for electron transport chain (ETC) complexes. By stabilising cardiolipin:cytochrome c interactions, SS-31 prevents cytochrome c from adopting a peroxidase conformation that generates reactive oxygen species (ROS). This preserves cristae structure, maintains ETC supercomplex assembly, and restores ATP synthesis efficiency. Rather than scavenging existing ROS, SS-31 prevents their generation at the source.
SS-31 has shown efficacy in preclinical models of ischaemia-reperfusion injury, heart failure, chronic kidney disease, skeletal muscle atrophy, and age-related mitochondrial decline. Clinical data from the PROGRESS-HF trial demonstrated improved exercise capacity in heart failure patients. Ongoing research includes sarcopenia, Alzheimer's disease, and diabetic nephropathy.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
